ABVX Stock Overview
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ABIVAX Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €13.46 |
| 52 Week High | €19.70 |
| 52 Week Low | €7.89 |
| Beta | 1.46 |
| 1 Month Change | -4.13% |
| 3 Month Change | 16.03% |
| 1 Year Change | -16.91% |
| 3 Year Change | -37.97% |
| 5 Year Change | 34.73% |
| Change since IPO | -35.90% |
Recent News & Updates
Recent updates
Is ABIVAX Société Anonyme (EPA:ABVX) A Risky Investment?
Apr 24
Is ABIVAX Société Anonyme (EPA:ABVX) Using Too Much Debt?
Jun 07An Intrinsic Calculation For ABIVAX Société Anonyme (EPA:ABVX) Suggests It's 28% Undervalued
Dec 11Is ABIVAX Société Anonyme (EPA:ABVX) Using Too Much Debt?
Jun 06A Quick Analysis On ABIVAX Société Anonyme's (EPA:ABVX) CEO Salary
Dec 31
Shareholder Returns
| ABVX | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -2.6% | -0.3% | 2.3% |
| 1Y | -16.9% | -15.9% | 6.0% |
Return vs Industry: ABVX underperformed the French Biotechs industry which returned -15.9% over the past year.
Return vs Market: ABVX underperformed the French Market which returned 6% over the past year.
Price Volatility
| ABVX volatility | |
|---|---|
| ABVX Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.6% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ABVX has not had significant price volatility in the past 3 months.
Volatility Over Time: ABVX's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 61 | Marc M. de Garidel | www.abivax.com |
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
ABIVAX Société Anonyme Fundamentals Summary
| ABVX fundamental statistics | |
|---|---|
| Market cap | €846.87m |
| Earnings (TTM) | -€147.74m |
| Revenue (TTM) | €4.49m |
188.5x
P/S Ratio-5.7x
P/E RatioIs ABVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABVX income statement (TTM) | |
|---|---|
| Revenue | €4.49m |
| Cost of Revenue | €0 |
| Gross Profit | €4.49m |
| Other Expenses | €152.23m |
| Earnings | -€147.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 09, 2024
| Earnings per share (EPS) | -2.35 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,288.23% |
| Debt/Equity Ratio | 37.7% |
How did ABVX perform over the long term?
See historical performance and comparison